Haywood analyst Gianluca Tucci reiterated a Buy rating on WELL Health Technologies Corp yesterday and set a price target of C$8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gianluca Tucci has given his Buy rating due to a combination of factors tied to WELL Health’s operational strength and growth profile. He highlights that the company posted record patient volumes in Canada with robust double‑digit year‑over‑year and organic growth, driven by both same‑clinic performance and the integration of newly absorbed locations. Tucci also underscores that physician headcount is expanding faster than the overall provider base, which he interprets as an indicator of rising capacity and higher revenue potential per visit.
In addition, Tucci views the early signs of margin improvement in the Primary Care segment as particularly important, suggesting that WELL is beginning to unlock operating leverage from its expanding clinic network. This combination of strong underlying demand, disciplined network expansion, favorable provider mix, and emerging EBITDA margin gains supports his conviction that WELL can continue compounding earnings. Taken together, these dynamics underpin his Buy recommendation on the stock.
In another report released on April 15, Stifel Nicolaus also maintained a Buy rating on the stock with a C$8.00 price target.
WELL’s price has also changed moderately for the past six months – from C$4.900 to C$4.370, which is a -10.82% drop .